The phase III CheckMate 067 study looked at patient-reported quality-of-life outcomes in patients with advanced melanoma undergoing immunotherapy treatment.
Researchers tested a combination regimen of bevacizumab with carboplatin and paclitaxel as a first-line treatment for patients with advanced mucosal melanoma.
Researchers tested standard-dose pembrolizumab plus ipilimumab at 50-mg or 100-mg doses in patients with previously untreated advanced melanoma.
It may be possible to double the number of patients eligible for clinical trials for advanced lung cancer by expanding trial eligibility criteria based on new technologies and advances in supportive care.
A new agent that targets Nectin-4, a protein found in 97% of urothelial cancers, may be an option for patients with locally advanced or metastatic forms of urothelial cancer.
The phase III KEYNOTE-048 study compared pembrolizumab plus chemotherapy vs the EXTREME regimen in patients with recurrent/metastatic head and neck cancer.
Researchers tested the novel oral fluoropyrimidine derivative S-1 plus oxaliplatin vs S-1 plus cisplatin in patients with diffuse-type or mixed-type advanced gastric adenocarcinoma.
Researchers are reporting that previous racial disparities in timely cancer treatment between African American and white patients practically disappeared in states where Medicaid access was expanded under the ACA.
The phase III ENZAMET study showed 'practice-changing' results with enzalutamide for men with metastatic hormone-sensitive prostate cancer.
A longer progression-free survival with FOLFOXIRI plus bevacizumab was noted in patients with metastatic colorectal cancer with poor prognosis.